Questionnaire

1. Many individuals with T2DM experience progressive metabolic deterioration and end-organ damage long before diagnosis:

2. CKD affects approximately what percentage of the global population?

3. The leading cause of CKD is:

4. After the introduction of combination therapy intended to shorten the time to reach personalised treatment targets, patients should be regularly assessed at what interval?

5. Which agent/agents are specifically recommended to slow CKD progression and reduce cardiovascular events in diabetes patients?

6. CKD is defined by the KDIGO 2022 guidelines as abnormalities in kidney structure or function persisting for more than how many months?

7. In T2DM patients with CKD, which of the following is/are an essential component of glycaemic management?

8. DPP-4 inhibitors are generally unsafe to use across all CKD stages:

9. Long-acting insulin analogues such as insulin glargine, insulin detemir and insulin degludec have an onset of action within approximately how long?

10. During the 36-week maintenance phase of the CONCLUDE study, both IDeg and Gla-300 showed comparable reductions in which of the following parameters in adults with T2DM: